These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 8873218)
1. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218 [TBL] [Abstract][Full Text] [Related]
2. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268 [TBL] [Abstract][Full Text] [Related]
3. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacoz-Aigrain E; Krishnamoorthy R Br J Clin Pharmacol; 1995 Oct; 40(4):361-7. PubMed ID: 8554938 [TBL] [Abstract][Full Text] [Related]
4. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Gaedigk A; Fuhr U; Johnson C; Bérard LA; Bradford D; Leeder JS Pharmacogenomics; 2010 Jan; 11(1):43-53. PubMed ID: 20017671 [TBL] [Abstract][Full Text] [Related]
5. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816 [TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Løvlie R; Daly AK; Matre GE; Molven A; Steen VM Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030 [TBL] [Abstract][Full Text] [Related]
7. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947 [TBL] [Abstract][Full Text] [Related]
8. A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles. Okubo M; Murayama N; Miura J; Shimizu M; Yamazaki H Clin Chim Acta; 2012 Oct; 413(19-20):1675-7. PubMed ID: 22634574 [TBL] [Abstract][Full Text] [Related]
9. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Steen VM; Molven A; Aarskog NK; Gulbrandsen AK Hum Mol Genet; 1995 Dec; 4(12):2251-7. PubMed ID: 8634695 [TBL] [Abstract][Full Text] [Related]
10. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Gaedigk A; Gotschall RR; Forbes NS; Simon SD; Kearns GL; Leeder JS Pharmacogenetics; 1999 Dec; 9(6):669-82. PubMed ID: 10634130 [TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Sachse C; Brockmöller J; Bauer S; Roots I Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586 [TBL] [Abstract][Full Text] [Related]
13. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Chida M; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T Pharmacogenetics; 1999 Jun; 9(3):287-93. PubMed ID: 10471060 [TBL] [Abstract][Full Text] [Related]
14. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. Løvlie R; Daly AK; Molven A; Idle JR; Steen VM FEBS Lett; 1996 Aug; 392(1):30-4. PubMed ID: 8769309 [TBL] [Abstract][Full Text] [Related]
15. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population. Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247 [TBL] [Abstract][Full Text] [Related]
16. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001 [TBL] [Abstract][Full Text] [Related]
17. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Stüven T; Griese EU; Kroemer HK; Eichelbaum M; Zanger UM Pharmacogenetics; 1996 Oct; 6(5):417-21. PubMed ID: 8946473 [TBL] [Abstract][Full Text] [Related]
18. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Endrizzi K; Fischer J; Klein K; Schwab M; Nüssler A; Neuhaus P; Eichelbaum M; Zanger UM Anal Biochem; 2002 Jan; 300(2):121-31. PubMed ID: 11779102 [TBL] [Abstract][Full Text] [Related]
19. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis. Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509 [TBL] [Abstract][Full Text] [Related]
20. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]